offer atorvastatin 20 mg for the primary or secondary prevention of CVD to people with CKD
increase the dose if a greater than 40% reduction in non-HDL cholesterol is not achieved and eGFR is 30 ml/min/1.73 m2 or more
agree the use of higher doses with a renal specialist if eGFR is less than 30 ml/min/ 1.73 m2
offer statins to people with CKD for the secondary prevention of CVD irrespective of baseline lipid values
antiplatelet drugs
offer antiplatelet drugs to people with CKD for the secondary prevention of CVD. CKD is not a contraindication to the use of low dose aspirin but clinicians should be aware of the increased risk of minor bleeding in people with CKD given multiple antiplatelet drugs
consider apixaban in preference to warfarin in people with a confirmed eGFR of 30-50 ml/min/1.73 m2 and non-valvular atrial fibrillation who have 1 or more of the following risk factors:
prior stroke or transient ischaemic attack
age 75 years or older
hypertension
diabetes mellitus
symptomatic heart failure
there is insufficient evidence to recommend the routine use of drugs to lower uric acid in people with CKD who have asymptomatic hyperuricaemia
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.